Measles Virus as an Oncolytic Immunotherapy.
Reads0
Chats0
TLDR
Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity as discussed by the authors, and live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics.Abstract:
Measles virus (MeV) preferentially replicates in malignant cells, leading to tumor lysis and priming of antitumor immunity. Live attenuated MeV vaccine strains are therefore under investigation as cancer therapeutics. The versatile MeV reverse genetics systems allows for engineering of advanced targeted, armed, and shielded oncolytic viral vectors. Therapeutic efficacy can further be enhanced by combination treatments. An emerging focus in this regard is combination immunotherapy, especially with immune checkpoint blockade. Despite challenges arising from antiviral immunity, availability of preclinical models, and GMP production, early clinical trials have demonstrated safety of oncolytic MeV and yielded promising efficacy data. Future clinical trials with engineered viruses, rational combination regimens, and comprehensive translational research programs will realize the potential of oncolytic immunotherapy.read more
Citations
More filters
Journal ArticleDOI
Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.
TL;DR: In this article, the authors discuss the use of oncolytic viruses (OVs) to overcome challenges in BiTE therapy, including limited bioavailability and severe toxicities have so far hampered broader clinical application, especially against solid tumors.
Journal ArticleDOI
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.
TL;DR: In this paper, the authors discuss strategies that are explored to further improve oncolytic virotherapy, including the combination of OVs with current immunotherapies to convert "immune cold" tumors to "immune-hot" will almost certainly improve the potency of OV.
Journal ArticleDOI
Oncolytic viruses: challenges and considerations in an evolving clinical landscape.
Ulrich M. Lauer,Julia Beil +1 more
TL;DR: This review will focus on the challenges of developing a successful OV and translation to clinical practice, discussing the innovative strategies that are being used to optimize the potential of OVs.
Journal ArticleDOI
Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme
TL;DR: A review of the most recent literature on the various available treatment options such as surgery, radiotherapy, cytotoxic chemotherapy, gene therapy, immunotherapy, phototherapy, nanotherapy, and tumor treating fields in the treatment of Globlastoma multiforme (GBM) is presented in this paper .
Journal ArticleDOI
Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies
Dirk M. Nettelbeck,Mathias F. Leber,Mathias F. Leber,Jennifer Altomonte,Assia L. Angelova,Julia Beil,Susanne Berchtold,Maike Delic,Jürgen Eberle,Anja Ehrhardt,Christine E. Engeland,Christine E. Engeland,Christine E. Engeland,Henry Fechner,Karsten Geletneky,Katrin Goepfert,Per Sonne Holm,Stefan Kochanek,Florian Kreppel,Lea Krutzke,Florian Kühnel,Karl S. Lang,Antonio Marchini,Markus Moehler,Michael D. Mühlebach,Ulrike Naumann,Roman Nawroth,Jürg P. F. Nüesch,Jean Rommelaere,Ulrich M. Lauer,Guy Ungerechts,Guy Ungerechts,Guy Ungerechts +32 more
TL;DR: A review of the state-of-the-art oncolytic vector gene therapy in Germany can be found in this article, where the authors provide an overview of the recent research activities of the German community of virotherapists.
References
More filters
Journal ArticleDOI
Repression of Heat Shock Transcription Factor HSF1 Activation by HSP90 (HSP90 Complex) that Forms a Stress-Sensitive Complex with HSF1
TL;DR: It is concluded that Hsp90, by itself and/or associated with multichaperone complexes, is a major repressor of HSF1, which can be activated by nonnative protein, heat, and geldanamycin.
Journal ArticleDOI
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas,Reinhard Dummer,Igor Puzanov,Ari M. Vanderwalde,Robert H.I. Andtbacka,Olivier Michielin,Anthony J. Olszanski,Josep Malvehy,Jonathan Cebon,Eugenio Fernandez,John M. Kirkwood,Thomas F. Gajewski,Lisa Chen,Kevin S. Gorski,Abraham Anderson,Scott J. Diede,Michael E. Lassman,Jennifer Gansert,F. Stephen Hodi,Georgina V. Long +19 more
TL;DR: The findings suggest that oncolytic virotherapy may improve the efficacy of anti-PD-1 therapy by changing the tumor microenvironment.
Journal ArticleDOI
Modulation of neurodegeneration by molecular chaperones.
TL;DR: It is proposed that molecular chaperones are neuroprotective because of their ability to modulate the earliest aberrant protein interactions that trigger pathogenic cascades.
Journal ArticleDOI
Rescue of measles viruses from cloned DNA.
Frank Radecke,Pius Spielhofer,Henriette Schneider,Karin Kaelin,M. Huber,C. Dötsch,G. Christiansen,Martin A. Billeter +7 more
TL;DR: This system, in principle, should be applicable to the rescue of any member of the large virus order Mononegavirales, i.e. viruses with a nonsegmented negative‐strand RNA genome.
Journal ArticleDOI
History of Oncolytic Viruses: Genesis to Genetic Engineering
TL;DR: Examination of early oncolytic virotherapy before genetic engineering serves to highlight tremendous advances, yet also hints at ways to penetrate host immune defenses, a significant remaining challenge in modern viroTherapy research.